ACIU Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
AC Immune SA (ACIU) is not a strong buy at the moment for a beginner, long-term investor. The financial performance is weak with significant YoY declines in revenue, net income, and EPS. The technical indicators are mixed, showing no clear bullish momentum, and there is no strong positive sentiment or catalysts from options, news, or trading trends. Given the lack of compelling reasons to invest immediately, holding off on this stock is recommended.
The MACD histogram is positive but contracting, suggesting weakening momentum. RSI is neutral at 37.959, and moving averages are bullish (SMA_5 > SMA_20 > SMA_200). However, the stock has dropped 3.87% in the regular market, and the price is hovering near the pivot level of 2.736, indicating no strong upward momentum.
Gross margin remains at 100%, showing operational efficiency. The stock has a 5.74% chance of gaining in the next month based on historical candlestick patterns.
No recent news or insider activity to boost sentiment. Hedge funds and insiders are neutral, and there is no congress trading data. The stock dropped 3.87% in the regular market, reflecting weak investor confidence.
In Q3 2025, revenue dropped to $939,000 (-96.32% YoY), net income fell to -$15.86M (-388.17% YoY), and EPS dropped to -0.16 (-420% YoY). Gross margin remained flat at 100%. Overall, the financial performance is significantly weak.
No recent analyst ratings or price target changes available for evaluation.
